Looking at antibody levels of infection naive individuals, we see continued waning in younger age groups* but increases in antibody levels in those aged >50 due to winter booster/4th dose.
With a similar trend seen in previously infected individuals, more noticeable in older age groups where the majority of individuals have antibodies >25,000!
We might need a new category to break up those >25,000....
* - some younger individuals will have boosting due to 4th dose eligibility, e.g. HCWs
Our latest SARS-CoV-2 serosurveillance data for England with @NHSBT (Oct-Dec 2022) is now out in the @UKHSA vaccine surveillance report.
Anti-nucleocapsid seropositivity: 82.5 % (c/f 78.2%)
Anti-spike seropositivity: 99.9% (c/f 99.8%)
https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports
2022 was epic. Eternally grateful to work with a brilliant team and colleagues in UKHSA and our collaborators, doing some fun and exciting science along the way 👩🔬👨🔬
Wishing you all a happy new year. Here's to 2023! 🎉
We're now looking in further detail into Ab/Ag binding in MPOX, with comparisons to Smallpox-vaccinated, as a way to understand these subtle differences but also what these mean for pan-pox immunity.. Hopefully more soon!
This was a massive collaborative piece of work, with thanks to colleagues across @UKHSA, @EPS_Porton, @RIPL_Porton, @CDCgov, @ImperialNHS & @ChelwestFT!
..and this pool gives some excellent sensitivity (97.14%) and specificity (98.23%), better than individual antigens (some being ~50% sens)
Using this assay we can also perform endpoint titrations to allow quantification of responses to Smallpox vaccine or MPOX infection 👇